Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-M7824 PET imaging in advanced NSCLC
NCT04297748Phase 2Terminated
- Sponsor
- Olivia Newton-John Cancer Research Institute
- Start
- Jun 2020
- Primary completion
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of bintrafusp alfa in non-small cell lung cancer (NSCLC), sponsored by Olivia Newton-John Cancer Research Institute. Started Jun 2020; status: terminated.
02
Drugs
bintrafusp alfa
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04297748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04297748.